<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325479</url>
  </required_header>
  <id_info>
    <org_study_id>152014</org_study_id>
    <nct_id>NCT02325479</nct_id>
  </id_info>
  <brief_title>Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI)</brief_title>
  <official_title>Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI) a Randomised Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Egyptian IVF-ET Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Egyptian IVF-ET Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin also has the ability to bind with and modulate a wide variety of proteins, which can&#xD;
      influence a number of physiological processes involved in implantation &amp; trophoblastic&#xD;
      development. These processes include adhesion of the blastocyst to the endometrial surface &amp;&#xD;
      trophoblastic differentiation &amp; invasion.&#xD;
&#xD;
      A recent Cochrane review hinted towards research to study the possible effects of the local&#xD;
      (uterine), &amp; NOT SYSTEMIC application of heparin during Assisted reproductive technology&#xD;
      (ART). Based on the above evidence the investigators hypothesize that low molecular weight&#xD;
      heparin given intrauterine at mock embryo transfer after oocyte pick up will help improve&#xD;
      pregnancy rates in patients undergoing ART.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following ethical approval of the committee of Egyptian IVF-ET center, a pilot prospective&#xD;
      randomized controlled study will include 40 patients, in which the study arm (group A ) will&#xD;
      be injected with LMWH intrauterine during mock embryo transfer, just after ovum pickup, while&#xD;
      the control arm (group B) will be injected intrauterine with similar volume tissue culture&#xD;
      media (G.2 plus ref. 10132, Vitrolife) also after ovum pickup. Admission into either group&#xD;
      will be through randomization after inclusion &amp; exclusion criteria have been met and before&#xD;
      start of controlled ovarian stimulation protocol.&#xD;
&#xD;
      The standard long gonadotrophin-releasing hormone (GnRH) agonist protocol will be used for&#xD;
      patients with predicted normal response based on clinical &amp; hormonal profile ; 1 mg of&#xD;
      leuprolide acetate daily s.c injection (Lucrin ®; Abbott, Hoofddorp, The Netherlands) is&#xD;
      applied from the mid luteal phase onward till the day of human chorionic gonadotropin (HCG)&#xD;
      injection.&#xD;
&#xD;
      Gonadotropins in the form of human menopausal gonadotropin (HMG) (Merional ®, IBSA, Institut&#xD;
      Biochimique SA, Lugano, Switzerland) will be given by intramuscular injection (IM) from the&#xD;
      2nd day of menstruation, The starting dose range from 150 to 450 IU depending on the basal&#xD;
      follicle stimulating hormone (FSH) level, Antral follicle count (AFC) , Patient's age and&#xD;
      body mass index (BMI).&#xD;
&#xD;
      In all protocols, stimulation is monitored by trans vaginal ultrasonography and serial&#xD;
      estradiol (E2) measurements starting from day 7 of the cycle and the gonadotropin dose is&#xD;
      adjusted individually according to follicular response.&#xD;
&#xD;
      After the development of at least three leading follicles≥18 mm, 10,000 unit of HCG&#xD;
      (Choriomon, IBSA, Institut Biochimique SA) is given IM, and a trans-vaginal ultrasound-guided&#xD;
      oocyte retrieval is performed 36 hours later.&#xD;
&#xD;
      After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter&#xD;
      (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi&#xD;
      S.A Paris, France) will be given intrauterine in group A patients.&#xD;
&#xD;
      LMWH is safe in pregnancy, category B drug , and given empirically sometimes in luteal phase&#xD;
      and in early 1st trimester without reported problems, it has a half life of 4 Hours, and&#xD;
      therefore it should not have any negative effects on developing embryos as it will not be&#xD;
      present at the time of transfer while already performing it s desired effect on the&#xD;
      endometrium.&#xD;
&#xD;
      The dose of LMWH given was calculated comparatively according to the work done by our group&#xD;
      Mansour et.al, 2011, where intrauterine administration 500 IU of HCG improved the&#xD;
      implantation and pregnancy rates.&#xD;
&#xD;
      Given the fact that this has not been attempted before, the best way to compare two different&#xD;
      drugs is through biological activity. So if the investigators want to use 500 IU of LMWH, and&#xD;
      knowing that In the in vitro purified system, enoxaparin sodium has a high anti Xa activity&#xD;
      (approximately 100 IU/mg), so to get 500 IU of LMWH we need 5mg. Clexane 20mg is packed in a&#xD;
      0.2ml syringe, And therefore the investigators need to inject 0.05ml intrauterine using&#xD;
      labotec catheter. (1/4 OF THE ORIGINAL SYRINGES CONTENT..i.e 5mg).&#xD;
&#xD;
      The control arm (group B) will be injected intrauterine with similar volume of tissue culture&#xD;
      media (G.2 plus ref. 10132, Vitrolife) Oocytes are then fertilized in vitro using ICSI and&#xD;
      after three to five days embryo transfer will be done using labotec catheter (Labotec,&#xD;
      Gottingen Germany) with ultrasound guidance.&#xD;
&#xD;
      Progesterone pessaries 400 mg twice daily (Cyclogest 400mg ®Actavis plc. Dublin, Ireland) is&#xD;
      given as a luteal support starting from the day of embryo transfer and continued for 16 days&#xD;
      after.&#xD;
&#xD;
      Pregnancy is defined as the occurrence of a positive β-HCG &gt;10 IU on day 12 after embryo&#xD;
      transfer and a second higher value 2 days later, followed by ultrasonography confirmation of&#xD;
      cardiac activity at 6 weeks gestation&#xD;
&#xD;
      A third party not involved in the actual study will moniter progress of the results and&#xD;
      record them. Study will be stopped if more than 10 consecutive patients fail to get pregnant&#xD;
      in the LMWH group. If the pregnancy rate &gt;25% in the intervention group by the end of 20&#xD;
      cases, then recruitment willl continue till 60 patients are enrolled on each study arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>14 days</time_frame>
    <description>safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early miscarriage rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implanation rate</measure>
    <time_frame>3 weeks after ET</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi S.A Paris, France) will be given intrauterine in group A patients, 500 IU of LMWH which is 5mg, in 0.05 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control arm (group B) will be injected intrauterine with similar volume of tissue culture media (G.2 plus ref. 10132, Vitrolife)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enaoxaprin sodium</intervention_name>
    <description>intrauterine administration after oocyte pickup as the main experimental intervention</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Clexane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tissue culture media</intervention_name>
    <description>intrauterine administration after oocyte pickup as placebo</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>(G.2 plus ref. 10132, Vitrolife)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Normal serum prolactin level &amp; thyroid stimulating hormone (TSH)&#xD;
&#xD;
          2. Unexplained infertility&#xD;
&#xD;
          3. Tubal factor infertility&#xD;
&#xD;
          4. BMI &lt;30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Reduced ovarian reserve by AFC, Anti-mullerian hormone (AMH)&#xD;
&#xD;
          2. Presence of non disconnected hydrosalpinges&#xD;
&#xD;
          3. Frozen embryo transfer cycles&#xD;
&#xD;
          4. Uterine Anomalies&#xD;
&#xD;
          5. Submucous fibroids and polyps&#xD;
&#xD;
          6. Uterine synechia&#xD;
&#xD;
          7. Contraindication of pregnancy e.g.: Somatic and mental diseases, which are&#xD;
             contraindications for carrying of a pregnancy and childbirth, inborn malformations or&#xD;
             acquired deformations of uterus cavity which make embryo implantation or carrying of a&#xD;
             pregnancy impossible ,ovarian tumors&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona M Aboulghar, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVF consultant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Egyptian IVF-ET Center</name>
      <address>
        <city>Cairo</city>
        <state>Maadi</state>
        <zip>11431</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Akhtar MA, Sur S, Raine-Fenning N, Jayaprakasan K, Thornton J, Quenby S, Marjoribanks J. Heparin for assisted reproduction: summary of a Cochrane review. Fertil Steril. 2015 Jan;103(1):33-4. doi: 10.1016/j.fertnstert.2014.09.005. Epub 2014 Oct 1. Review.</citation>
    <PMID>25282470</PMID>
  </reference>
  <reference>
    <citation>Mansour R, Tawab N, Kamal O, El-Faissal Y, Serour A, Aboulghar M, Serour G. Intrauterine injection of human chorionic gonadotropin before embryo transfer significantly improves the implantation and pregnancy rates in in vitro fertilization/intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril. 2011 Dec;96(6):1370-1374.e1. doi: 10.1016/j.fertnstert.2011.09.044. Epub 2011 Nov 1.</citation>
    <PMID>22047664</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Egyptian IVF-ET Center</investigator_affiliation>
    <investigator_full_name>Mona Aboulghar</investigator_full_name>
    <investigator_title>Professor Obstetrics and Gynecology Fetal Medicine unit Cairo University, IVF Consultant Egyptian IVF center -Maadi Cairo</investigator_title>
  </responsible_party>
  <keyword>Low Molecular Weight (LMWH) Heparin ICSI Enaoxaprin sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

